ワクチン

Details: Category: ワクチン; Published: 05 October 2016; Hits: 25943

User Rating: 3 / 5

October 5, 2016

　This international collaborative project by VLP Therapeutics, Nagasaki University and National Institute of Infectious diseases (NIID), supported by Global Health Innovation Technology [GHIT] Fund, is a pre-clinical study to investigate safety and immunogenicity of a virus-like particle (VLP)-based vaccine against Dengue virus infection.

Tetsuro Matano, AIDS Research Center, April 2, 2013

HIV-EM The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations including England and Rwanda. The SeV vector AIDS vaccine system has been developed by AIDS Research Center, National Institute of Infectious Diseases and Institute of Medical Science, University of Tokyo.

Press release from IAVI on April 1, 2013

http://www.iavi.org/Information-Center/Press-Releases/Pages/IAVI-AND-PARTNERS-INITIATE-PHASE-I-TRIAL-OF-A-NOVEL-AIDS-VACCINE-REGIMEN.aspx

Information on this project in IAVI Web

http://www.iavi.org/Information-Center/Publications/Pages/AIDS-Vaccine-Development-in-Japan.aspx

Infectious Deseases

Basic Research

Surveillance

Information

GHIT has announced to award an investment to a project for development of a Dengue vaccine by VLP Therapeutics in collaboration with Nagasaki University and NIID.

The start of a Phase I clinical trial of an HIV vaccine candidate

Tetsuro Matano, AIDS Research Center, April 2, 2013

Press release from IAVI on April 1, 2013

Information on this project in IAVI Web